FDA pushes off ticagrelor decision for three more months
The FDA has extended the time to complete its review of the new drug application (NDA) for ticagrelor (Brilinta, AstraZeneca) from Sept. 16 to Dec. 16.

The London-based AstraZeneca said it will “continue to work closely with the FDA to support the review of the ticagrelor NDA.”

Ticagrelor is currently under regulatory review in nine additional global territories, including the European Union, Canada and Brazil.

Ticagrelor (Brilinta/Brilique), an investigational oral antiplatelet treatment for acute coronary syndromes, is a direct-acting P2Y12 receptor antagonist in a chemical class called cyclo-pentyl-triazolo-pyrimidines.

Ticagrelor is a reversibly-binding oral ADP receptor antagonist. The PLATO (PLATelet inhibition and patient Outcomes) study found that ticagrelor decreased incidences of cardiovascular death, MI and stroke when compared with clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-Aventis).

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup